Amgen to acquire Dark Blue Therapeutics for up to $840Mnews2026-01-06T15:49:45+00:00January 6th, 2026|Endpoints News|
Protagonist ‘strongly leaning’ toward opting out of Takeda profit-sharing dealnews2026-01-06T14:34:45+00:00January 6th, 2026|Endpoints News|
Lilly goes back to Nimbus for an oral obesity drug in $55M dealnews2026-01-06T13:00:47+00:00January 6th, 2026|Endpoints News|
Cartography does another pharma deal, this time with Pfizernews2026-01-06T12:30:19+00:00January 6th, 2026|Endpoints News|
Sanofi doubles down on Earendil in $160M near-term dealnews2026-01-05T15:03:58+00:00January 5th, 2026|Endpoints News|
Servier taps Insilico’s AI platform for early cancer R&Dnews2026-01-05T10:34:25+00:00January 5th, 2026|Endpoints News|
AbbVie does T cell engager deal in China for Zelgen’s DLL3-targeted drugnews2025-12-31T16:18:48+00:00December 31st, 2025|Endpoints News|
Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drugnews2025-12-24T12:11:48+00:00December 24th, 2025|Endpoints News|
Windward gets bispecific from Qyuns in its second China deal of the yearnews2025-12-22T15:46:03+00:00December 22nd, 2025|Endpoints News|
Shionogi to pay $2.5B to acquire one of the only approved ALS drugsnews2025-12-22T15:45:39+00:00December 22nd, 2025|Endpoints News|
